Rija Jafar*
Metabolic Syndrome (MetS) is a cluster of metabolic abnormalities including obesity, hypertension, dyslipidemia, and insulin resistance, which significantly increases the risk of cardiovascular diseases and type 2 diabetes. Recent research has focused on natural remedies to mitigate these conditions, with Stigma Maydis (cornsilk) emerging as a potential therapeutic agent due to its bioactive compounds, such as flavonoids, alkaloids, and phenolic acids. This study aims to assess the therapeutic potential of Stigma Maydis in managing MetS. Through a comprehensive review of existing literature, we highlight its anti-inflammatory, antioxidant, and hypoglycemic properties that may help in reducing the components of MetS. Animal and human trials have shown that cornsilk can positively influence weight management, blood pressure regulation, lipid profiles, and insulin sensitivity. Furthermore, its minimal side effects position it as a promising adjunct to conventional therapies. This abstract provides a critical evaluation of the current evidence, identifying the mechanisms through which Stigma Maydis exerts its beneficial effects and discussing future research directions to fully establish its role in treating MetS.
PDFShare this article
Journal of Metabolic Syndrome received 48 citations as per Google Scholar report
